Background: With the new highly active drugs available for people with multiple sclerosis
(pwMS), vaccination becomes an essential part of the risk management strategy Objective …

Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …

Background COVID-19 vaccination is recommended for patients with multiple sclerosis
(pwMS), while disease-modifying therapies (DMTs) may influence the efficacy of SARS-CoV …

Background and Objective Depleting CD20+ B cells is the primary mechanism by which
ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the …

Objectives To evaluate whether a third vaccination shows an added effect on severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple …

Background and purpose With the new highly active drugs available for people with multiple
sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy …

Background Adequate response to the SARS-CoV-2 vaccine represents an important
treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID …

Patients suffering from neuro-inflammatory diseases such as multiple sclerosis (MS) and
neuromyelitis optica spectrum disorders (NMOSD) remain vulnerable to COVID-19. We …

Objective To compare “hybrid immunity”(prior COVID‐19 infection plus vaccination) and post‐
vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …

Background Anti-CD20 is a highly effective therapy for multiple sclerosis (MS), a disease
with multiple abnormalities in function of B and T cells and innate immune cells. Anti-CD20 …